Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Auteur de référence en rhumatologie
30 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
136 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
34
34 articles ont été cités au moins 34fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Total citations reçues
3 843
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
109
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
73
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
EHPAD RESIDENCE AZUR
27-29 RUE YOURI GAGARINE, 92700 COLOMBES
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Journal of pediatric gastroenterology and nutrition · 2022
There is a need for consensus on the recommendations for follow‐up of children and adolescents with celiac disease.Objectives:To gather the current evidence and to offer recommendations for follow‐up and management.Methods:The Special Interest Group on Celiac Diseases of the European Society of Paediatric Gastroenterology Hepatology and Nutrition formulated ten questions considered to be essential for follow‐up care. A literature search (January 2010–March 2020) was performed in PubMed or Medline. Relevant publications were identified and potentially eligible studies were assessed. Statements and recommendations were developed and discussed by all coauthors. Recommendations were voted upon: joint agreement was set as at least 85%.Results:Publications (n = 2775) were identified and 164 were included. Using evidence or expert opinion, 37 recommendations were formulated on: The need to perform follow‐up, its frequency and what should be assessed, how to assess adherence to the gluten‐free diet, when to expect catch‐up growth, how to treat anemia, how to approach persistent high serum levels of antibodies against tissue‐transglutaminase, the indication to perform biopsies, assessment of quality of life, management of children with unclear diagnosis for which a gluten‐challenge is indicated, children with associated type 1 diabetes or IgA deficiency, cases of potential celiac disease, which professionals should perform follow‐up, how to improve the communication to patients and their parents/caregivers and transition from pediatric to adult health care.Conclusions:We offer recommendations to improve follow‐up of children and adolescents with celiac disease and highlight gaps that should be investigated to further improve management.
Journal of translational medicine · 2022
Abstract Background Triple negative breast cancer (TNBC) is an aggressive disease characterized by high risk of relapse and development of resistance to different chemotherapy agents. Several targeted therapies have been investigated in TNBC with modest results in clinical trials. Among these, PI3K/AKT inhibitors have been evaluated in addition to standard therapies, yielding conflicting results and making attempts on elucidating inherent mechanisms of resistance of great interest. Increasing evidences suggest that PI3K/AKT inhibitors can induce autophagy in different cancers. Autophagy represents a supposed mechanism of drug-resistance in aggressive tumors, like TNBC. We, therefore, investigated if two PI3K/AKT inhibitors, ipatasertib and taselisib, could induce autophagy in breast cancer models, and whether chloroquine (CQ), a well known autophagy inhibitor, could potentiate ipatasertib and taselisib anti-cancer effect in combination with conventional chemotherapy. Methods The induction of autophagy after ipatasertib and taselisib treatment was evaluated in MDAMB231, MDAM468, MCF7, SKBR3 and MDAB361 breast cancer cell lines by assaying LC3-I conversion to LC3-II through immunoblotting and immunofluorescence. Other autophagy-markers as p62/SQSTM1 and ATG5 were evaluated by immunoblotting. Synergistic antiproliferative effect of double and triple combinations of ipatasertib/taselisib plus CQ and/or paclitaxel were evaluated by SRB assay and clonogenic assay. Anti-apoptotic effect of double combination of ipatasertib/taselisib plus CQ was evaluated by increased cleaved-PARP by immunoblot and by Annexin V- flow cytometric analysis. In vivo experiments were performed on xenograft model of MDAMB231 in NOD/SCID mice. Results Our results suggested that ipatasertib and taselisib induce increased autophagy signaling in different breast cancer models. This effect was particularly evident in PI3K/AKT resistant TNBC cells, where the inhibition of autophagy by CQ potentiates the therapeutic effect of PI3K/AKT inhibitors in vitro and in vivo TNBC models, synergizing with taxane-based chemotherapy. Conclusion These data suggest that inhibition of authophagy with CQ could overcome mechanism of drug resistance to PI3K/AKT inhibitors plus paclitaxel in TNBC making the evaluation of such combinations in clinical trials warranted.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Revista espanola de enfermedades digestivas · 2025 · Journal Article
Marset G, Fornos S, Masip E, Calzado MÁ, et al.
Antibiotics (Basel, Switzerland) · 2025 · Journal Article
Cornistein W, Balasini C, Nuccetelli Y, Rodriguez VM, et al.
Archives of disease in childhood · 2024 · Journal Article
Roca M, Masip E, Colombo C, Boon M, et al.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2023 · Journal Article
Larriba R, Roca M, Masip E, Cañada-Martínez A, et al.
Journal of pediatric gastroenterology and nutrition · 2022 · Journal Article
Donat E, Roca M, Castillejo G, Sánchez-Valverde F, et al.
Journal of pediatric gastroenterology and nutrition · 2022 · Journal Article
Mearin ML, Agardh D, Antunes H, Al-Toma A, et al.
European journal of nutrition · 2021 · Journal Article
Roca M, Donat E, Masip E, Crespo-Escobar P, et al.
Nutrients · 2021 · Clinical Trial
Calvo-Lerma J, Boon M, Hulst J, Colombo C, et al.
Journal of clinical medicine · 2021 · Journal Article
Roca M, Donat E, Rodriguez Varela A, Carvajal E, et al.
Pediatric research · 2021 · Journal Article
Calvo-Lerma J, Roca M, Boon M, Colombo C, et al.
Scientific reports · 2020 · Journal Article
Roca M, Rodriguez Varela A, Carvajal E, Donat E, et al.
Cell death & disease · 2026 · Journal Article
Lombardi R, Addi L, Pucci B, Bruzzese F, et al.
Brain & spine · 2026 · Journal Article
Miedema S, Lovaglio Rivas AC, Bourguet M, Roca M, et al.
Journal of translational medicine · 2025 · Journal Article
Costantini S, Romeo I, Fanelli G, Roca MS, et al.
Cell death & disease · 2025 · Journal Article
Antibiotics (Basel, Switzerland) · 2025 · Journal Article
Cornistein W, Balasini C, Nuccetelli Y, Rodriguez VM, et al.
Antimicrobial agents and chemotherapy · 2025 · Journal Article
Cornistein W, Balasini C, Nuccetelli Y, Rodriguez VM, et al.
International journal of geriatric psychiatry · 2020 · Letter
Dorman G, Alvarez Dengra A, Fiorini A, Failla B, et al.
Scientific reports · 2020 · Journal Article
Roca M, Rodriguez Varela A, Carvajal E, Donat E, et al.
Molecular and clinical oncology · 2022 · Case Reports
Hernando J, Riera-Arnau J, Roca M, Garcia A, et al.
BMC cancer · 2024 · Clinical Trial Protocol
Budillon A, Leone A, Passaro E, Silvestro L, et al.
Journal of clinical pharmacy and therapeutics · 2021 · Journal Article
Miarons M, Roca M, Salvà F
Journal of clinical pharmacy and therapeutics · 2021 · Journal Article
Miarons M, Roca M, Salvà F
Community mental health journal · 2022 · Journal Article
Ciampa MA, Roca M, Lysaght R
Large oncosomes overexpressing integrin alpha-V promote prostate cancer adhesion and invasion via AKT activation
Abstract Background Molecular markers for prostate cancer (PCa) are required to improve the early definition of patient outcomes. Atypically large extracellular vesicles (EVs), referred as “Large Oncosomes” (LO), have be
Adaptation marginale de restaurations avec de composites/adhésifs libres de Bis-GMA en cavités préparées à la fraise et avec laser Er:YAG
Cette étude a évalué l'adaptation marginale des restaurations obturées par des composites/adhésifs sans Bis-GMA dans des cavités préparées à l'aide d'une fraise et de lasers Er:YAG. Des cavités de cl V ont été préparées
HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation
Abstract Background Pancreatic ductal adenocarcinoma (PDAC) represents an unmet clinical need due to the very poor prognosis and the lack of effective therapy. Here we investigated the potential of domatinostat (4SC-202)
Additional file 6 of Genomic profiling of a collection of patient-derived xenografts and cell lines identified ixabepilone as an active drug against chemo-resistant osteosarcoma
Supplementary Material 6
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
Roca MS, Lombardi R, Testa C, Iannelli F, et al.
Journal of experimental & clinical cancer research : CR · 2025 · Journal Article
Manara MC, Bruzzese F, Formentini L, Landuzzi L, et al.
Clinical and experimental medicine · 2023 · Journal Article
Giner-Pérez L, Donat E, Sinisterra-Sebastián P, Masip E, et al.
Journal of translational medicine · 2022 · Journal Article
Cocco S, Leone A, Roca MS, Lombardi R, et al.
Clinical and experimental immunology · 2022 · Journal Article
Roca M, Donat E, Masip E, Ballester V, et al.
Frontiers in immunology · 2021 · Journal Article
Tan IL, Coutinho de Almeida R, Modderman R, Stachurska A, et al.
European journal of gastroenterology & hepatology · 2021 · Journal Article
Donat E, Roca M, Masip E, Polo B, et al.
Brain sciences · 2021 · Journal Article
Gentile E, Delussi M, Abagnale C, Caponnetto V, et al.
Current oncology (Toronto, Ont.) · 2022 · Journal Article
Martí C, Yébenes L, Oliver JM, Moreno E, et al.
Frontiers in neurology · 2020 · Journal Article
Delussi M, Gentile E, Coppola G, Prudenzano AMP, et al.